Pharmaceutical

Risk adjusted net present value: What is the current valuation of AstraZeneca’s Saruparib?

Saruparib is a small molecule commercialized by AstraZeneca, with a leading Phase III program in Metastatic Prostate Cancer.

Mar 13, 2024 - 18:29
Saruparib is a small molecule commercialized by AstraZeneca, with a leading Phase III program in Metastatic Prostate Cancer.
Read the original article

Tags:

Previous Article

Eli Lilly’s Lebrikizumab Shows Promise in Eczema Treatment for Skin of Color

Next Article

Risk adjusted net present value: What is the current valuation of AstraZeneca’s ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

SGN-1 by Guangzhou Sinogen Pharmaceutical for Head And ...

Dec 4, 2023

Mitch McConnell’s abrupt episode has an important public health takeaway

Mitch McConnell’s abrupt episode has an important publi...

Jul 28, 2023

STAT+: Medicare proceeds with plan to claw back hospital funds after Supreme Court decision

STAT+: Medicare proceeds with plan to claw back hospita...

Nov 3, 2023